title: Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.
abstract: OBJECTIVE
  The impact of concurrent chemotherapy on the local control in patients with T2N0 laryngeal cancer who receive radiation therapy (RT) was evaluated.
  
  
  METHODS
  Sixty-three patients with T2N0 laryngeal cancer who were treated by definitive RT were analyzed. The primary site of the cancer was the glottis in 50 patients, the supraglottis in 9 patients, and the subglottis in 4 patients. Thirty-six patients were treated by RT alone and the remaining 27 patients received concurrent chemoradiotherapy (CRT).
  
  
  RESULTS
  Complete response (CR) was obtained in 92% of the patients who received RT alone and 100% of the patients who received CRT. Voice preservation in the group who received CRT (89%) was significantly higher than that in the group treated by RT alone (61%). The 5-year disease-free survival rates in those who received concurrent CRT was significantly superior to that in the patients who received RT alone, although no significant difference was seen in the cause-specific survival rate between the 2 groups. The multivariate analysis revealed that the treatment method (RT alone vs. CRT) was the most significant risk factor that predicted recurrence after RT.
  
  
  CONCLUSIONS
  Concurrent CRT had a positive impact on the local control of T2N0 laryngeal cancer.
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. takimoto@showa.gunma-u.ac.jp
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Akimoto
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nonaka
authors.forename: Yoshizumi
authors.initials: Y
authors.lastname: Kitamoto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ninomiya
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chikamatsu
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Furuya
authors.forename: Kazushige
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Norio
authors.initials: N
authors.lastname: Mitsuhashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D014833:Voice Quality
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin